Business Context and Reporting Period
Company: Elevai Labs Inc. (Note: Metadata referenced "PMGC Holdings Inc." but the filing text identifies the registrant as Elevai Labs Inc., trading as ELAB on Nasdaq).
Filing Type: Form 8-K (Current Report)
Date of Report: October 21, 2024
Event: Entry into a Material Definitive Agreement (Item 1.01). Elevai Biosciences Inc., a subsidiary of the Company, entered into a Master Services Agreement (MSA) with KCRN Research, Inc., a global contract research organization.
Key Financial Metrics
This filing is a current report regarding a contractual agreement and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these financial indicators.
Material Changes and Agreement Details
The primary material change is the execution of the MSA and Work Order No. 1 to support the development of an Investigational New Drug (IND) application for EL-22, a recombinant bacterium targeting obesity and muscle loss preservation.
- Counterparty: KCRN Research, Inc.
- Scope of Services: Clinical and regulatory services structured in three phases:
- Phase 1: Submit a pre-IND meeting request to the FDA.
- Phase 2: Prepare and submit the pre-IND package (contingent on meeting grant).
- Phase 3: Attend the pre-IND meeting.
- Term: Three (3) years from October 21, 2024, with automatic one-year renewals unless terminated.
- Compensation: KCRN receives value upon certain contingent events at each phase; specific dollar amounts are not disclosed in the summary text.
- Termination: Either party may terminate work orders with 30 days' written notice. The MSA may be terminated for material breach or insolvency.
Guidance, Outlook, and Risks
Outlook: The agreement is designed to facilitate the initial regulatory pathway for EL-22. Success depends on FDA engagement and the completion of specific work order phases.
Risks and Contingencies:
- Forward-Looking Statements: The filing contains forward-looking statements regarding future events (e.g., FDA meetings, IND submission) which are subject to risks and uncertainties.
- Regulatory Uncertainty: Progress is contingent on FDA granting a pre-IND meeting and the successful preparation of regulatory packages.
- Contractual Risk: The agreement is subject to termination for material breach, insolvency, or by notice.
Investor Verification Checklist
- Verify the specific financial terms and total potential cost of the MSA and Work Order No. 1 in the attached Exhibits 10.1 and 10.2.
- Confirm the current cash position of Elevai Labs Inc. to assess ability to fund contingent payments under the MSA.
- Review the "Risk Factors" section in the Company's most recent 10-K or 10-Q for detailed risks regarding EL-22 development.
- Monitor future filings for the outcome of the Phase 1 pre-IND meeting request.